No Data
No Data
Optimistic Buy Rating for Pharvaris on Advancement in Phase 3 HAE Treatment Trial
Pharvaris Price Target Maintained With a $35.00/Share by Wedbush
Pharvaris Price Target Maintained With a $35.00/Share by Wedbush
Wedbush Reiterates Outperform on Pharvaris, Maintains $35 Price Target
Wedbush analyst Laura Chico reiterates Pharvaris (NASDAQ:PHVS) with a Outperform and maintains $35 price target.
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)
Pharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial Prospects
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks ZUG,
No Data